Trial Profile

Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Cladribine Plus LDAC Alternating With 5-Azacitidine With Venetoclax in Patients With Untreated AML

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cladribine (Primary) ; Cytarabine (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use

11 Apr 2025 Planned End Date changed from 30 Apr 2025 to 30 Apr 2027.
11 Apr 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Apr 2027.
12 Dec 2023 Results of subgroup analysis (From Nov 2018-Apr 2023, n=124 pts ) presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com